Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy

Young J. Kim

Research output: Contribution to journalArticle

Abstract

The correlation between tumor-infiltrating lymphocyte (TIL)-expression of programmed cell death ligand 1 (PD-L1) and clinical responsiveness to the PD-1 blocking antibody nivolumab implicates adaptive immune evasion mechanisms in cancer. We review our findings that tumor cell PD-L1 expression is induced by interferon γ (IFNγ) producing TILs. We provide a mechanistic rationale for combining IFNγ+ T helper type 1 (Th1)-inducing cancer vaccines with PD-1 immune checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalOncoImmunology
Volume3
Issue number12
DOIs
StatePublished - Dec 2 2014

Keywords

  • adaptive immune resistance
  • anti-PD-1
  • cancer vaccine
  • TLR agonists
  • tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy'. Together they form a unique fingerprint.

  • Cite this